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Abstract 
Epicardial adipose tissue thickness (EATT) is suggested as a novel marker of subclinical atherosclerosis. Despite 
increased carotid intima-media thickness (CIMT) in autosomal dominant polycystic kidney disease (ADPKD) patients, 
the extent of the relationship between CIMT and EATT is unknown. The main purpose of our study was to evaluate 
the relation between EATT and CIMT in normotensive ADPKD patients with well-preserved renal function. Fifty-five 
normotensive ADPKD patients with normal renal function and 50 healthy control subjects were included in the study. 
EATT and CIMT were measured by echocardiography in all subjects. Correlation between EATT and CIMT was evalu-
ated in ADPKD patients, while multivariate linear regression analysis was performed to determine factors predicting 
EATT and CIMT. ADPKD patients had significantly higher levels CIMT [0.7 (0.4–1.2) vs. 0.5 (0.4–0.8) mm, p < 0.001] and 
EATT (6.8 ± 2.7 vs. 4.8 ± 1.2 mm, p < 0.001) as compared with control subjects. Significant positive correlation was 
found between EATT and CIMT (r = 0.58, p < 0.001). Higher CRP levels (OR 54.7, 95 % CI 37.44–72.01, p < 0.001) and 
having ADPKD (OR 10.2, 95 % CI 2.53–17.86, p = 0.01) were the only independent factors associated with a higher 
EATT. A higher age (OR 0.35, 95 % CI −0.02 to 0.71, p = 0.06) tended to be independently associated with a higher 
EATT. In conclusion, our findings suggest that EATT, being simply measured by echocardiography and correlated with 
CIMT, can be used to detect subclinical atherosclerosis in normotensive ADPKD patients.
Keywords: Autosomal dominant polycystic kidney disease, Preserved renal function, Early atherosclerosis, Epicardial 
adipose tissue thickness, Carotid intima-media thickness
© 2016 Sag et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made.
Background
Autosomal dominant polycystic kidney disease 
(ADPKD), one of the most common hereditary diseases, 
is an important cause of end-stage renal disease (ESRD) 
(Schrier 2006; Ecder and Schrier 2009), while frequently 
associated with cardiovascular diseases as the leading 
cause of morbidity and mortality in ADPKD patients 
(Ecder and Schrier 2004, 2009; Grantham 2008).
Endothelial dysfunction (ED) is an early and reversible 
manifestation of atherosclerosis with multifactorial eti-
ology. Arterial stiffness with increased vascular smooth 
muscle tone and intima media thickness (IMT) is related 
to ED (Widlansky et  al. 2003; Sag et  al. 2015; Turkmen 
et al. 2008; Yildiz et al. 2014). Given that ED develops in 
both normotensive and hypertensive ADPKD patients 
preceding the beginning of renal failure (Peterson et  al. 
2013), atherosclerosis has been considered to play a key 
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role in the early phases of cardiovascular injury identified 
in the pathogenesis of ADPKD (Schrier 2006; Turkmen 
et al. 2008; Yildiz et al. 2014).
In this regard, identification of the mechanisms respon-
sible for ED becomes important given the likelihood of 
early treatment and thus improved cardiovascular prog-
nosis among affected ADPKD patients (Ecder and Schrier 
2009; Peterson et  al. 2013). Besides ED, other markers 
including LVH and carotid artery IMT (CIMT) have been 
used in past studies with normotensive ADPKD to show 
subclinical organ damage (Turkmen et  al. 2008; Mar-
tinez-Vea et al. 2000; Kocyigit et al. 2014).
CIMT is a well-known independent predictor of car-
diovascular diseases and recognized as a novel marker of 
subclinical atherosclerosis (Polak et al. 2011). In addition, 
on the basis of its strong correlation with obesity, insulin 
resistance, metabolic syndrome, hypertension, diabetes, 
and subclinical atherosclerosis (Polak et al. 2011; Iacobel-
lis and Willens 2009); echocardiographic measurement of 
epicardial adipose tissue thickness (EATT) has also been 
indicated to be a potential marker of atherosclerosis and 
of CIMT and thus might be used as a simple tool for pre-
dicting cardiometabolic risk (Polak et  al. 2011; Iacobel-
lis and Willens 2009; Altun et  al. 2014; Chaowalit et  al. 
2006).
While EATT is positively correlated with CIMT in sev-
eral diseases (Iacobellis and Willens 2009; Altun et  al. 
2014; Natale et al. 2009; Kim et al. 2013), to our knowl-
edge no data are available on the potential role of EATT 
in predicting early atherosclerosis as well as CIMT in 
patients with ADPKD. Therefore, our study was designed 
to evaluate the relationship between echocardiographic 
EATT and CIMT, as predictors of early atherosclerosis, 
in normotensive ADPKD patients.
Methods
Study population
Between July 2013 and July 2015, 115 ADPKD patients 
who were registered by the Uludag University School of 
Medicine in the Turkish Nephrology Society Cystic Kid-
ney Disease Working Group Registry were evaluated for 
the study. Fifty-five normotensive ADPKD patients with 
normal renal function (mean ± SD age 38 ± 11.4 years, 
26 males, 29 females) and 45 age- and sex-matched 
healthy subjects (mean ±  SD age 38.6 ±  10.1  years, 24 
males, 26 females) were included in the study. ADPKD 
was diagnosed and defined according to the ultrasono-
graphic criteria published by Pei et  al. (2009) and all 
patients had a positive family history of ADPKD. Pres-
ence of impaired renal function (estimated GFR, <60 mL/
min/1.73 m2), hyperlipidemia, hypertension, or any car-
diovascular disease, a measured office blood pressure 
≥140/90  mmHg and usage of antihypertensive drugs 
were the exclusion criteria. After a detailed explanation 
each patient signed an informed consent form in accord-
ance with the declaration of Helsinki. The local ethics 
committee of Uludag University approved the study.
Study parameters
Data on patient demographics, anthropometrics [weight 
(kg), height (cm), body mass index (BMI; kg/m2)], vital 
signs [systolic blood pressure (mmHg), diastolic blood 
pressure (mmHg), pulse (bpm)], blood biochemistry 
[BUN (mg/dL), creatinine (mg/dL), uric acid (mg/dL), 
estimated glomerular filtration rate (GFR; mL/min), total 
cholesterol (mg/dL), HDL cholesterol (mg/dL), LDL cho-
lesterol (mg/dL), triglycerides (mg/dL), uric acid (mg/
dL) and high-sensitivity C-reactive protein (hs-CRP; mg/
dL)], left ventricul ejection fraction (LVEF; %), left ven-
tricular mass (LVM; g), CIMT (mm) and EATT (mm) 
were recorded in patient and control groups. Correla-
tion between EATT and CIMT was evaluated in ADPKD 
patients, while multivariate linear regression analysis was 
performed to determine factors predicting EATT and 
CIMT.
Measurements
After an overnight fasting venous blood samples were 
taken for biochemical analysis. Blood samples were ana-
lyzed for plasma glucose, BUN, creatinine, uric acid, 
total cholesterol, LDL-cholesterol, HDL-cholesterol 
and triglycerides using an autoanalyzer (Aeroset System 
Operations Manual; Abbot Laboratories, Abbott Park, 
IL, USA). The solid phase enzyme linked immunosorb-
ent assay (ELISA) method was used with a High Sensitiv-
ity CRP Enzyme Immunoassay (DRG International Inc., 
Mountainside, NJ, USA) for the measurement of high-
sensitivity C-reactive protein (hs-CRP). Estimated GFR 
was calculated based on the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation (Levey 
et al. 2009).
Echocardiography investigation
Two-dimensional (2D) transthoracic echocardiography 
was performed with a widely available transducer and 
equipment (M3S probe, Vivid 7, GE-Vingmed, Horten, 
Norway), by standard techniques, with subjects at rest, 
in the left lateral decubitus position. The EATT measure-
ments were performed as previously defined by Iacobel-
lis et  al. (2003). The relatively echo-free space between 
the myocardial outer wall and the visceral pericardium 
on the anterior wall of the right ventricle at end-systole 
in the parasternal long-axis view was defined as EATT. 
The LVEF and LVM were calculated according to Ameri-
can Society of Echocardiography Guidelines (Lang et al. 
2005).
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CIMT was measured from 10 mm proximal to the right 
common carotid artery bifurcation segment, using the 
same device with a 12 MHz linear-array imaging probe. 
Carotid IMT was calculated as the distance between the 
lumen–intima and media–adventitia interfaces. Analy-
sis was based on average of three consecutive measure-
ments. The same expert cardiologist, unaware of the 
clinical data, performed and calculated EATT and CIMT. 
Intra-observer reproducibility was determined using a 
Spearman correlation coefficient. In our echo laboratory, 
the intra-observer correlation coefficients were 0.92 for 
CIMT and 0.91 for EATT, representing good reproduc-
ibility and reliability.
Statistical analysis
Normality of distribution of the data was analyzed using 
Kolmogorov–Smirnov test. Categorical data were pre-
sented as numbers and percentages and were compared 
by Chi square test. Continuous data were presented as 
median (interquartile range) or mean ± standard devia-
tions according to normality of distribution. Comparison 
of continuous data was performed using Mann–Whitney 
U or Student t tests as needed. Receiver operator char-
acteristics curve was performed to define a cutoff level 
for EATT with optimal sensitivity and specificity to dis-
tinguish patients with ADPKD and controls. Spearman 
or Pearson tests were used for correlation analyses. Vari-
ables with a significant correlation with EATT in the 
univariate models were included in multivariate linear 
regression analysis to determine independent correlates 
of EATT. Among BP measurements, only strongest cor-
relate of EATT was included in the model to avoid mul-
ticolinearity. A correlation coefficient of 0.1–0.3 was 
considered as weak, 0.3–0.5 as moderate, and >0.5 as 
strong correlation. A two-sided p value <0.05 was consid-
ered as statistically significant.
Results
Demographic, anthropometric and vital characteristics 
in study groups
Patient and control groups were similar in terms of age 
and gender distribution (Table  1). ADPKD patients had 
similar BMI, smoking rate and BP levels when compared 
with control subjects.
Blood biochemistry in study groups
ADPKD patients had similar BUN, creatinine, estimated 
GFR, total cholesterol, HDL-cholesterol LDL-cholesterol 
and triglycerides levels as compared with control subjects 
(Table  1). ADPKD patients had significantly higher lev-
els for hs-CRP [0.42 (0.22–1.19) vs. 0.31 (0.13–0.9) mg/
dL, p < 0.001] and uric acid (4.8 ± 1.5 vs. 3.2 ± 0.9 mg/
Table 1 Clinical and laboratory characteristics of ADPKD patients and control subjects
ADPKD autosomal dominant polycystic kidney disease, GFR glomerular filtration rate, CIMT carotid intima-media thickness, EAT epicardial adipose tissue, hs-CRP high 
sensitive C-reactive protein, HDL high density lipoprotein, LDL Low density lipoprotein
a Blood pressure measurements were performed at the office
The results in italics identify the statistically significant values
ADPKD patients (n = 55) Controls (n = 50) p value
Age (years) 38 ± 11.4 38.6 ± 10.1 0.674
Gender (males/females) 26/29 24/26 0.548
Body mass index (kg/m2) 24.1 ± 3.4 23.1 ± 2.9 0.327
Smoking (%) 34 34.5 0.559
Systolic blood pressure (mmHg)a 123.2 ± 10.1 122.9 ± 7.4 0.873
Diastolic blood pressure (mmHg)a 75.7 ± 9.1 76.8 ± 6.8 0.499
BUN (mg/dL) 12 (8–28) 11 (7–24) 0.176
Creatinine (mg/dL) 0.76 ± 0.16 0.75 ± 0.11 0.881
Estimated GFR (mL/min) 107 ± 17 111 ± 17 0.270
Total cholesterol (mg/dL) 180 ± 28 179 ± 24 0.352
HDL cholesterol (mg/dL) 43.8 ± 8.4 45 ± 9.3 0.569
LDL cholesterol (mg/dL) 106 ± 28 104 ± 30 0.404
Triglycerides (mg/dL) 114 (44–700) 115 (43–333) 0.985
Uric acid (mg/dL) 4.8 ± 1.5 3.2 ± 0.9 <0.001
hs-CRP (mg/dL) 0.42 (0.22–1.19) 0.31 (0.13–0.9) <0.001
Left ventricul ejection fraction (%) 72 (60–82) 70 (65–82) 0.009
Left ventricular mass (g) 188 ± 55 154 ± 36 <0.001
CIMT (mm) 0.7 (0.4–1.2) 0.5 (0.4–0.8) <0.001
EAT thickness (mm) 6.8 ± 2.7 4.8 ± 1.2 <0.001
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dL, p  <  0.001) levels as compared with control subjects 
(Table 1).
Echocardiographic and ultrasonographic findings in study 
groups
ADPKD patients had significantly higher levels for 
LVEF [72 (60–82) vs. 70 (65–82)  %, p  =  0.009], LVM 
(188 ± 55 vs. 154 ± 36 g, p < 0.001), CIMT [0.7 (0.4–1.2) 
vs. 0.5 (0.4–0.8) mm, p < 0.001], and EATT (6.8 ± 2.7 vs. 
4.8 ± 1.2 mm, p < 0.001) as compared with control sub-
jects (Table 1).
Correlation between EATT and CIMT
There was a significant positive correlation between 
EATT and CIMT (r = 0.58, p < 0.001) (Fig. 1).
Multivariate linear regression analysis for factors 
predicting EATT and CIMT
Variables correlated in the univariate models with EATT 
were listed in Table  2. Multivariate linear regression 
analysis revealed independent correlates of EATT as 
having ADPKD (OR 10.2, 95 % CI 2.53–17.86, p = 0.01) 
and hs-CRP (OR 54.7, 95 % CI 37.44–72.01, p < 0.001). 
A higher age tended to be independently associated 
with a higher EATT (p =  0.06). Independent correlates 
of CIMT were increased EATT (OR 0.02, 95 % CI 0.01–
0.04, p = 0.006), having ADPKD (OR 0.86, 95 % CI 0.2–
1.6, p =  0.02), older age (OR 0.04, 95  % CI 0.004–0.07, 
p = 0.03) and lower HDL-cholesterol (OR −0.03, 95 % CI 
[−0.06] to [−0.004], p = 0.03).
Receiver operating characteristics curve analysis was 
performed to describe optimal cut-off level for EATT 
with optimal sensitivity and specificity to distinguish 
patients with ADPKD and controls. Receiver opera-
tor characteristics curve (AUC under the curve 0.74, 
p < 0.001) analysis showed that an EATT of 51.5 mm or 
higher was 69 % sensitive and 70 % specific to distinguish 
between patients with ADPKD and controls (Fig. 2).
Discussion
Our findings in a cohort of normotensive ADPKD 
patients with well-preserved renal function revealed 
higher levels for LVEF, LVM and serum uric acid levels 
in patient than in controls. Additionally, hs-CRP, CIMT 
Fig. 1 Correlation between epicardial adipose tissue thickness (EATT) and carotid intima-media thickness (CIMT) in patients with ADPKD
Page 5 of 7Sag et al. SpringerPlus  (2016) 5:211 
and EATT levels were higher in ADPKD patients as com-
pared with controls. Besides a significant positive cor-
relation between CIMT and EATT levels, presence of 
ADPKD was determined to be an independent predictor 
both increased EATT and CIMT levels, while increased 
EATT also predicted the increased CIMT levels.
As mentioned earlier, our ADPKD patients have higher 
levels of LVM, even though they have similar arterial BP 
levels compared to the control group. This finding is sup-
ported by several other studies, and development of LVH 
in normotensive ADPKD patients may have caused by 
several reasons including; renin-angiotensin-aldosterone 
system activation, adrenergic stimulation, endothelial 
dysfunction and diastolic dysfunction (Ecder and Schrier 
2009; Martinez-Vea et al. 2000; Kocyigit et al. 2014; Pie-
trzak-Nowacka et al. 2012; Chapman et al. 1997). In addi-
tion, preserved LVEF points to the presence of diastolic 
dysfunction. However, we did not evaluate left ventricu-
lar diastolic function in the study.
Likewise, numerous clinical reports confirmed the 
association between the echocardiographic EATT and 
cardiovascular risk factors, both traditional and novel, as 
well as with atherosclerotic disease (Kocyigit et al. 2014; 
Polak et  al. 2011; Iacobellis and Willens 2009; Iacobel-
lis et al. 2003; Lang et al. 2005; Kankaanpaa et al. 2006). 
Hence, echocardiographic measurement of EATT has 
been considered amongst the markers of early athero-
sclerosis (Iacobellis et al. 2008), while shown to be asso-
ciated with increased CIMT in patients with metabolic 
syndrome (MetS) (Sengul et  al. 2011), correlated with 
CIMT and arterial stiffness better than waist circumfer-
ence in hypertensive subjects (Natale et al. 2009), and the 
best independent predictor of CIMT in human immuno-
deficiency virus infection associated with MetS (Iacobel-
lis et al. 2007).
Our findings are consistent with data from past stud-
ies indicating presence of increased CIMT among both 
hypertensive and normotensive patients with ADPKD 
compared with healthy individuals (Widlansky et  al. 
2003; Sag et  al. 2015; Turkmen et  al. 2008). Although, 
EATT was shown to be positively correlated with CIMT 
in several diseases (Altun et al. 2014; Natale et al. 2009; 
Kim et al. 2013), our findings indicate potential of EATT 
to predict early atherosclerosis as well CIMT in ADPKD 
patients with well-preserved renal function for the first 
time in the literature.
Accordingly, being considered amongst markers of 
ED and thus of early atherosclerosis, increased levels 
for CIMT and EATT in our ADPKD patients with well-
preserved renal function emphasize that during ADPKD, 
subclinical organ damage starts earlier than renal impair-
ment (Ecder and Schrier 2009; Turkmen et  al. 2008; 
Peterson et al. 2013).
In this regard, our findings emphasize the potential 
value of echocardiographic EATT measurements in eval-
uating subclinical target organ damage, and thus the like-
lihood of implementing strategies to control unfavorable 
cardiovascular risk factors and the development of future 
Table 2 Multivariate linear regression analysis for  factors 
predicting EATT
Dependent variable: epicardial adipose tissue thickness (EATT)
ADPKD autosomal dominant polycystic kidney disease, BMI body mass index, BP 
blood pressure, GFR glomerular filtration rate, hs-CRP high sensitive C-reactive 
protein, LDL low density lipoprotein




r p OR p
Age 0.41 <0.001 0.35 ([− 0.02] to [0.71]) 0.06
ADPKD 0.417 <0.001 10.2 ([2.53] to [17.86]) 0.01
GFR −0.316 0.001 −0.17 ([− 0.39] to [0.04]) 0.11
BMI 0.29 0.002 0.87 ([− 0.2] to [1.94]) 0.11
Systolic BP 0.21 0.034 0.15 ([− 0.21] to [0.51]) 0.4
hs-CRP 0.512 <0.001 54.7 ([37.44] to [72.01]) <0.001
Uric acid 0.477 <0.001 0.05 ([− 2.85] to [2.96]) 0.9
LDL-C 0.216 0.027 −0.01 ([− 0.13] to [0.11]) 0.8
Fig. 2 Receiver operating characteristic (ROC) curve of epicardial 
adipose tissue thickness (EATT) measured by echocardiography for 
predicting ADPKD
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CVD in patients with increased EATT (Ecder and Schrier 
2009; Pei et al. 2009).
Besides, on the basis of the documented correla-
tion of eGFR to CRP in patients with CKD (Tong et  al. 
2007; Dubin et al. 2011), increased hs-CRP levels in our 
ADPKD patients with preserved renal function seems 
to indicate the likelihood of both CRP mediated inflam-
matory changes to occur at much earlier stages of renal 
disease. Also, positive correlation between EATT and hs-
CRP emphasize the independent association of epicardial 
fat with inflammatory markers (Altun et al. 2014; Mala-
vazos et al. 2008).
On the basis of several advantages such as simplicity, 
low cost, reliability, easy accessibility, rapid applicabil-
ity, and good reproducibility echocardiographic EATT 
measurement has been suggested to offer a routine way 
of evaluating atherosclerotic and cardiovascular risk in a 
clinical setting with likely correlation with cardiometa-
bolic risk factors and potential relevance in CAD and 
atherosclerotic vascular disease (Iacobellis and Willens 
2009). Even though, CIMT is a well-known marker of 
atherosclerosis, EATT measurement is easier than CIMT 
measurement in the real world. Since, an extra probe is 
required for CIMT measurement, EATT might become 
preferable. In this regard our findings indicate EATT may 
serve as a simple tool and an independent predictor of 
subclinical atherosclerosis in ADPKD patients with pre-
served renal function.
Certain limitations to this study should be considered. 
First, small sample size might be disadvantage in achiev-
ing the statistical significance about the independent 
correlates of EATT and CIMT as well as to apply results 
of the present regression models to the entire popula-
tion. Secondly, with the exception of hs-CRP, our study 
was lacking other oxidative stress markers. Thirdly, in 
our study, we only include patients with normotensive 
ADPKD with normal renal function, and excluded any 
other form of ADPKD. Another limitation is lack of long-
term follow-up of patients in terms of cardiovascular 
events. Finally, the cross-sectional design made it impos-
sible to establish any cause and effect relationships.
In conclusion, our findings indicate presence of early 
atherosclerotic changes in ADPKD patients with well-
preserved renal function based on identification of 
increased EATT and CIMT. Our findings suggest that 
EATT, being simply measured by echocardiography and 
correlated with CIMT, can be used as a first-line meas-
urement to detect early atherosclerosis in normotensive 
ADPKD patients. Further studies in large randomized 
populations are needed to improve our understanding 
pathophysiological mechanisms involved in early onset 
of ED in ADPKD patients with more robust and con-
vincing evidence regarding the diagnostic and predictive 
properties of echocardiographic EATT to be considered 
as a routine method of evaluating cardiovascular risk in a 
clinical setting.
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